The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Treatment of Irritable Bowel Syndrome

과민성 장증후군의 치료

  • Lee, Kwang-Jae (Department of Gastroenterology, Ajou University School of Medicine)
  • 이광재 (아주대학교 의과대학 소화기내과학교실)
  • Published : 2011.05.01
⟨ Previous Next ⟩

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal condition and its pathophysiology remains to be unestablished.Traditional symptom-based therapies of IBS are directed at the relief of individual IBS symptoms. Combinations of drugs to targetbothersome symptoms are suggested as the first-line pharmacologic treatment. Exclusion diets have modest efficacy in improvingsymptoms in some IBS patients. Dietary fiber, bulking agents, laxatives, antispasmodics and laxatives can be used for theimprovement of some individual symptoms including constipation, abdominal pain and diarrhea. $5HT_3$ receptor antagonists and5HT4 receptor agonists are effective in relief of global IBS symptoms and individual symptoms such as abdominal pain andabnormal bowel habits. A short term course of nonabsorbable antibiotics may be beneficial, particularly in patients withdiarrhea-predominant IBS. Some probiotics, tricyclic antidepressants and selective serotonin reuptake inhibitors may have somebenefits in relieving global IBS symptoms. The treatment strategies adequate for Korean patients with IBS are required.

Keywords

References

  1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidencebased position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-S35.
  2. Lee SY, Lee KJ, Kim SJ, Cho SW. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009;79:196-201. https://doi.org/10.1159/000211715
  3. Park DW, Lee OY, Shim SG, et al. The differences in prevalence and Sociodemographic Characteristics of Irritable Bowel syndrome according to Rome II and Rome III. J Neurogastroenterol Motil 2010;16:186-193. https://doi.org/10.5056/jnm.2010.16.2.186
  4. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(Suppl 2): S1-S9.
  5. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004;53:1459-1464. https://doi.org/10.1136/gut.2003.037697
  6. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006;25:514-522.
  7. Costabile A, Klinder A, Fava F, et al. Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr 2008;99:110-120.
  8. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337: a2313, doi: 10.1136/bmj.a2313.
  9. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979;1:376-378. https://doi.org/10.1136/bmj.1.6160.376
  10. Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. Ir Med J 1983;76:253.
  11. Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India 1984;32:1041-1044.
  12. Jalihal A, Kurian G. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol 1990; 5:507-513. https://doi.org/10.1111/j.1440-1746.1990.tb01432.x
  13. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 2009;339:b3154, doi: 10.1136/bmj.b3154.
  14. Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23: 191-196. https://doi.org/10.1111/j.1365-2036.2006.02705.x
  15. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 2006;24:183-205. https://doi.org/10.1111/j.1365-2036.2006.02938.x
  16. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80.
  17. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-84.
  18. Efskind PS, Bernklev T, Vatn MH. A double-blind placebocontrolled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-468. https://doi.org/10.3109/00365529609006766
  19. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-247. https://doi.org/10.1007/BF01296258
  20. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34.
  21. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-1740. https://doi.org/10.1001/archinte.161.14.1733
  22. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-2203. https://doi.org/10.1111/j.1572-0241.2004.30509.x
  23. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol 2004;2:675-682. https://doi.org/10.1016/S1542-3565(04)00284-8
  24. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a $5-HT_3$ receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-1159. https://doi.org/10.1046/j.1365-2036.1999.00610.x
  25. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-123. https://doi.org/10.1111/j.1572-0241.2005.40365.x
  26. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-1040. https://doi.org/10.1016/S0140-6736(00)02033-X
  27. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-1719. https://doi.org/10.1111/j.1572-0241.2007.01282.x
  28. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-2670. https://doi.org/10.1111/j.1572-0241.2001.04128.x
  29. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of $5-HT_3$ antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-1843; quiz 1844. https://doi.org/10.1038/ajg.2009.223
  30. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrheapredominant irritable bowel syndrome. Digestion 2008;77:225-235. https://doi.org/10.1159/000150632
  31. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-1211. https://doi.org/10.1080/00365520802240255
  32. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119-126. https://doi.org/10.1080/00365520310006748
  33. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-1666. https://doi.org/10.1046/j.1365-2036.2001.01094.x
  34. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-1888. https://doi.org/10.1046/j.1365-2036.2002.01372.x
  35. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-676. https://doi.org/10.1136/gut.52.5.671
  36. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-1713. https://doi.org/10.1136/gut.2005.070789
  37. Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2007;22:1183-1189. https://doi.org/10.1111/j.1440-1746.2006.04543.x
  38. Chey WD, Pare P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008;103:1217-1225. https://doi.org/10.1111/j.1572-0241.2008.01808.x
  39. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-563. https://doi.org/10.7326/0003-4819-145-8-200610170-00004
  40. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-174. https://doi.org/10.1007/s10620-007-9839-8
  41. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26:475-486. https://doi.org/10.1111/j.1365-2036.2007.03362.x
  42. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101: 1581-1590. https://doi.org/10.1111/j.1572-0241.2006.00734.x
  43. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367-378. https://doi.org/10.1136/gut.2008.163162
  44. Halpert A, Dalton CB, Diamant NE, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005;100:664-671. https://doi.org/10.1111/j.1572-0241.2005.30375.x